[
  {
    "ts": "2026-02-06T13:15:35+00:00",
    "headline": "The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
    "summary": "Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform. One Specialist, ... The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
    "url": "https://247wallst.com/investing/2026/02/06/the-tavr-pioneer-bets-everything-on-one-market-as-its-competitor-spreads-risk/",
    "source": "24/7 Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "84166d95-285f-358e-9b9f-57733af61cc3",
      "content": {
        "id": "84166d95-285f-358e-9b9f-57733af61cc3",
        "contentType": "STORY",
        "title": "The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
        "description": "",
        "summary": "Edwards Lifesciences (NYSE: EW) and Boston Scientific (NYSE: BSX) both reported strong quarters, but the results reveal fundamentally different strategies in the heart device market. Edwards doubled down on transcatheter valve replacement with $1.15 billion in TAVR sales, up 12.4%, while Boston Scientific exited TAVR entirely and leaned into its diversified cardiovascular platform. One Specialist, ... The TAVR Pioneer Bets Everything on One Market as Its Competitor Spreads Risk",
        "pubDate": "2026-02-06T13:15:35Z",
        "displayTime": "2026-02-06T13:15:35Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/24_7_wall_st__718/60982137a104719f1036d0c74377543b",
          "originalWidth": 1366,
          "originalHeight": 768,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Qd4XzRgGFfs9lFcCPVOHhg--~B/aD03Njg7dz0xMzY2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/24_7_wall_st__718/60982137a104719f1036d0c74377543b.cf.webp",
              "width": 1366,
              "height": 768,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FY9ItBLTfgfYc77uNIUF6A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/24_7_wall_st__718/60982137a104719f1036d0c74377543b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "24/7 Wall St.",
          "url": "https://247wallst.com/"
        },
        "canonicalUrl": {
          "url": "https://247wallst.com/investing/2026/02/06/the-tavr-pioneer-bets-everything-on-one-market-as-its-competitor-spreads-risk/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/tavr-pioneer-bets-everything-one-131535672.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            },
            {
              "symbol": "EW"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-06T13:08:03+00:00",
    "headline": "Boston Scientific price target lowered to $110 from $125 at Stifel",
    "summary": "Stifel lowered the firm’s price target on Boston Scientific (BSX) to $110 from $125 and keeps a Buy rating on the shares following the company’s quarterly report. Investors seem likely to wait for more visible signs of stability and a “what’s next” catalyst before “enthusiastically embracing the stock again,” the analyst contends.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and",
    "url": "https://finance.yahoo.com/news/boston-scientific-price-target-lowered-130803427.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "4dc4c5ff-a962-3227-a5a3-52640f2a08b6",
      "content": {
        "id": "4dc4c5ff-a962-3227-a5a3-52640f2a08b6",
        "contentType": "STORY",
        "title": "Boston Scientific price target lowered to $110 from $125 at Stifel",
        "description": "",
        "summary": "Stifel lowered the firm’s price target on Boston Scientific (BSX) to $110 from $125 and keeps a Buy rating on the shares following the company’s quarterly report. Investors seem likely to wait for more visible signs of stability and a “what’s next” catalyst before “enthusiastically embracing the stock again,” the analyst contends.Claim 50% Off TipRanks PremiumUnlock hedge fund-level data and powerful investing tools for smarter, sharper decisions Stay ahead of the market with the latest news and",
        "pubDate": "2026-02-06T13:08:03Z",
        "displayTime": "2026-02-06T13:08:03Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/boston-scientific-price-target-lowered-to-110-from-125-at-stifel-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/FTa8CtQV3vs7_S_EPzhwOA--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/KEvkicUgSm7sULbOJuMgBQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/6e60166f16c98d232e4fe2b08fd8a093.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-price-target-lowered-130803427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/boston-scientific-price-target-lowered-130803427.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BSX"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]